Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Systematic Reviews
Published in: Systematic Reviews 1/2021

Open Access 01-12-2021 | Protocol

Does surfactant nebulization prevent early intubation in preterm infants? A protocol for a systematic review and meta-analysis

Authors: Vincent D. Gaertner, Dirk Bassler, Christoph M. Rüegger

Published in: Systematic Reviews | Issue 1/2021

Login to get access

Abstract

Background

Respiratory distress syndrome (RDS) is the most common cause of respiratory failure in preterm infants. Treatment consists of respiratory support and exogenous surfactant administration. Commonly, surfactant is administered intratracheally. However, this requires airway instrumentation and subsequent fluid instillation which may be harmful. Surfactant nebulization (SN) may offer a safe and effective alternative for surfactant administration, but the clinical efficacy is not yet established. Thus, this systematic review and meta-analysis of randomized controlled trials will summarize the available evidence to determine the effectiveness and safety of SN for the prevention of intubation and subsequent mechanical ventilation at 72 h after birth.

Methods

A systematic literature search in Medline, Embase, and The Cochrane Library will be performed, and all randomized controlled trials (RCTs) and quasi-RCTs from published articles, presentations, and trial registries will be included in this meta-analysis. Titles and abstracts of all records identified in the search will be screened by two reviewers independently.
Data on preterm infants (≤ 37 weeks) receiving nebulized surfactant in the first 72 h after birth for the treatment or prevention of RDS will be evaluated. Primary outcome is the intubation rate by 72 h after birth, and secondary outcomes include peridosing safety effects as well as major neonatal morbidities.
Risk of bias will be assessed using the revised Cochrane ROB tool, and subgroup analyses will be performed to evaluate potential confounding factors. Publication bias will be assessed by examining a funnel plot. The meta-analysis will be performed using a fixed-effects model.

Discussion

This review will provide an evidence-based tool for information about surfactant nebulization, illustrating the current knowledge and hopefully revealing potential novel avenues for researchers and clinicians alike.

Systematic review registration

This review is registered with the publicly available resource PROSPERO (CRD42020175625).
Appendix
Available only for authorised users
Literature
1.
Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update. Neonatology. 2013;103(4):353–68.PubMedCrossRef
2.
EuroNeoStat. Annual report for very low gestational age infants 2010. Barakaldo, Spain: The ENS Project; 2010.
3.
4.
Smith LJ, McKay KO, van Asperen PP, Selvadurai H, Fitzgerald DA. Normal development of the lung and premature birth. Paediatr Respir Rev. 2010;11(3):135–42.PubMedCrossRef
5.
Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European consensus guidelines on the management of respiratory distress syndrome - 2016 Update. Neonatology. 2017;111(2):107–25.PubMedCrossRef
6.
Polin RA, Carlo WA, Committee on Fetus and Newborn, American Academy of Pediatrics. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics. 2014;133(1):156–63.PubMedCrossRef
7.
SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network SSG of the EKSNNR, Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362(21):1970–9.CrossRef
8.
Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet J-M, Carlin JB, et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008;358(7):700–8.PubMedCrossRef
9.
Dunn MS, Kaempf J, de Klerk A, de Klerk R, Reilly M, Howard D, et al. Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics. 2011;128(5):e1069–76.PubMedCrossRef
10.
Niemarkt HJ, Hütten MC, Kramer BW. Surfactant for respiratory distress syndrome: new ideas on a familiar drug with innovative applications. Neonatology. 2017;111(4):408–14.PubMedPubMedCentralCrossRef
11.
12.
Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics. 2013;131(2):e502–9.PubMedCrossRef
13.
Isayama T, Iwami H, McDonald S, Beyene J. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants. JAMA. 2016;316(6):611.PubMedCrossRef
14.
Göpel W, Kribs A, Härtel C, Avenarius S, Teig N, Groneck P, et al. Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants. Acta Paediatr. 2015;104(3):241–6.PubMedCrossRef
15.
Dijk PH, Heikamp A, Bambang Oetomo S. Surfactant nebulisation prevents the adverse effects of surfactant therapy on blood pressure and cerebral blood flow in rabbits with severe respiratory failure. Intensive Care Med. 1997;23(10):1077–81.PubMedCrossRef
16.
Klebermass-Schrehof K, Wald M, Schwindt J, Grill A, Prusa A-R, Haiden N, et al. Less invasive surfactant administration in extremely preterm infants: impact on mortality and morbidity. Neonatology. 2013;103(4):252–8.PubMedCrossRef
17.
Helwich E, Rutkowska M, Bokiniec R, Gulczyńska E, Hożejowski R. Intraventricular hemorrhage in premature infants with Respiratory Distress Syndrometreated with surfactant: incidence and risk factors in the prospective cohort study. Dev Period Med. 2017;21(4):328–35.PubMed
18.
Nayeri FS, Esmaeilnia Shirvani T, Aminnezhad M, Amini E, Dalili H, Moghimpour Bijani F. Comparison of INSURE method with conventional mechanical ventilation after surfactant administration in preterm infants with respiratory distress syndrome: therapeutic challenge. Acta Med Iran. 2014;52(8):596–600.PubMed
19.
Pillow JJ, Minocchieri S. Innovation in surfactant therapy II: surfactant administration by aerosolization. Neonatology. 2012;101(4):337–44.PubMedCrossRef
20.
Lewis JF, Ikegami M, Jobe AH, Tabor B. Aerosolized surfactant treatment of preterm lambs. J Appl Physiol. 1991;70(2):869–76.PubMedCrossRef
21.
Schermuly R, Schmehl T, Günther A, Grimminger F, Seeger W, Walmrath D. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury. Impact on gas exchange. Am J Respir Crit Care Med. 1997;156(2 Pt 1):445–53.PubMedCrossRef
22.
Hütten MC, Kuypers E, Ophelders DR, Nikiforou M, Jellema RK, Niemarkt HJ, et al. Nebulization of poractant alfa via a vibrating membrane nebulizer in spontaneously breathing preterm lambs with binasal continuous positive pressure ventilation. Pediatr Res. 2015;78(6):664–9.PubMedCrossRef
23.
Walther FJ, Hernández-Juviel JM, Waring AJ. Aerosol delivery of synthetic lung surfactant. PeerJ. 2014;e403:2.
24.
Wolfson MR, Wu J, Hubert TL, Mazela J, Gregory TJ, Clayton RG, et al. Dose-response to aerosolized KL4 surfactant in the spontaneously breathing CPAP-supported preterm lamb. Pediatr Res. 2011;70(S5):751.CrossRef
25.
Milesi I, Tingay DG, Lavizzari A, Bianco F, Zannin E, Tagliabue P, et al. Supraglottic atomization of surfactant in spontaneously breathing lambs receiving continuous positive airway pressure. Pediatr Crit Care Med. 2017;18(9):e428–34.PubMedCrossRef
26.
Milesi I, Tingay DG, Zannin E, Bianco F, Tagliabue P, Mosca F, et al. Intratracheal atomized surfactant provides similar outcomes as bolus surfactant in preterm lambs with respiratory distress syndrome. Pediatr Res. 2016;80(1):92–100.PubMedCrossRef
27.
28.
Bianco F, Ricci F, Catozzi C, Murgia X, Schlun M, Bucholski A, et al. From bench to bedside: in vitro and in vivo evaluation of a neonate-focused nebulized surfactant delivery strategy. Respir Res. 2019;20(1):134.PubMedPubMedCentralCrossRef
29.
Jorch G, Hartl H, Roth B, Kribs A, Gortner L, Schaible T, et al. Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonol. 1997;24(3):222–4.PubMedCrossRef
30.
Arroe M, Pedersen-Bjergaard L, Albertsen P, Bodé S, Greisen G, Jonsbo F, et al. Inhalation of aerosolized surfactant (exosurf) to neonates treated with nasal continuous positive airway pressure. Prenat Neonat Med. 1998;1998:346–52.
31.
Berggren E, Liljedahl M, Winbladh B, Andreasson B, Curstedt T, Robertson B, et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr. 2000;89(4):460–4.PubMedCrossRef
32.
Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R. An open label, pilot study of Aerosurf® combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv. 2010;23(5):303–9.PubMedCrossRef
33.
Minocchieri S, Berry CA, Pillow JJ, CureNeb Study T. Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2019;104(3):F313–9.PubMedCrossRef
34.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https://​doi.​org/​10.​1186/​2046-4053-4-1.
35.
Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92(4):529–34.PubMedCrossRef
36.
International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol (Chicago, Ill 1960). 2005;123(7):991–9.CrossRef
37.
38.
Bayley N. Bayley scales of infant and toddler development, third edition: Administration manual. San Antonio, TX: Harcourt; 2006.
39.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.PubMedCrossRef
40.
Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3. Med Decis Mak. 2013;33(5):618–40.CrossRef
41.
Abdel-Latif ME, Osborn DA. Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev. 2012;10:CD008310.
42.
More K, Sakhuja P, Shah PS. Minimally invasive surfactant administration in preterm infants. JAMA Pediatr. 2014;168(10):901.PubMedCrossRef
43.
Rutkowska M, Hożejowski R, Helwich E, Borszewska-Kornacka MK, Gadzinowski J. Severe bronchopulmonary dysplasia - incidence and predictive factors in a prospective, multicenter study in very preterm infants with respiratory distress syndrome. J Matern neonatal Med. 2019;32(12):1958–64.CrossRef
44.
Schmidt B, Asztalos EV, Roberts RS, Robertson CMT, Sauve RS, Whitfield MF, et al. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA. 2003;289(9):1124–9.PubMedCrossRef
45.
Fink JB, Macloughlin R, Telfer C, Clark A. Developing inhaled drugs for critically ill patients: a platform for all ages; 2016.
46.
Minocchieri S, Knoch S, Schoel WM, Ochs M, Nelle M. Nebulizing poractant alfa versus conventional instillation: ultrastructural appearance and preservation of surface activity. Pediatr Pulmonol. 2014;49(4):348–56.PubMedCrossRef
47.
Pohlmann G, Iwatschenko P, Koch W, Windt H, Rast M, de Abreu MG, et al. A novel continuous powder aerosolizer (CPA) for inhalative administration of highly concentrated recombinant surfactant protein-C (rSP-C) surfactant to preterm neonates. J Aerosol Med Pulm Drug Deliv. 2013;26(6):370–9.PubMedCrossRef
Metadata
Title
Does surfactant nebulization prevent early intubation in preterm infants? A protocol for a systematic review and meta-analysis
Authors
Vincent D. Gaertner
Dirk Bassler
Christoph M. Rüegger
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2021
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-020-01573-6

Other articles of this Issue 1/2021

Systematic Reviews 1/2021 Go to the issue

Protocol

The effect of preoperative stoma site marking on risk of stoma-related complications in patients with intestinal ostomy—protocol of a systematic review and meta-analysis

Methodology

A likelihood ratio test for the homogeneity of between-study variance in network meta-analysis

Research

Paper 3: Selecting rapid review methods for complex questions related to health policy and system issues

Protocol

Patient-reported outcome measures in pediatric palliative care—a protocol for a scoping review

Protocol

Impact of child development at primary school entry on adolescent health—protocol for a participatory systematic review

Research

Barriers and enablers to physical activity in patients during hospital stay: a scoping review